"10.1371_journal.pone.0037374","plos one","2012-05-15T00:00:00Z","Ariadna Mendoza-Naranjo; Peter Cormie; Antonio E Serrano; Rebecca Hu; Shay O'Neill; Chiuhui Mary Wang; Christopher Thrasivoulou; Kieran T Power; Alexis White; Thomas Serena; Anthony R J Phillips; David L Becker","Department of Cell and Developmental Biology, University College London, London, United Kingdom; CoDa Therapeutics, Auckland, New Zealand; Newbridge Medical Research Corp, Warren, Pennsylvania, United States of America","Conceived and designed the experiments: AMN ARJP DLB. Performed the experiments: AMN PC AES RH SO CMW CT KTP TS DLB. Analyzed the data: AMN AES RH CT DLB. Contributed reagents/materials/analysis tools: TS AW ARJP. Wrote the paper: AMN ARJP DLB. Obtained ethics for human tissue: TS AW.","The authors have read the journals policy and have the following conflicts: The patented antisense technology targeting Cx43 is being developed by CoDa Therapeutics Inc which is currently in phase2B clinical trial treating venous leg ulcers. Patent: DL Becker and CR Green PCT No. WO 00/44409 USA No. PCT/GB00/00238 Formulations comprising antisense nucleotides to connexins. New Zealand patent 513154 awarded, Australia 21193, USA09/890363, Canada 2361251, Europe 901236 and Japan 00/595711. DLB holds shares in CoDa and RH, SO, AW and ARJP are employed by CoDa. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","Ariadna Mendoza-Naranjo","AMN",12,TRUE,3,10,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
